This study was supported by grants from the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases (2015B050501003), Guangdong Provincial Engineering Center For Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease, Guangdong Provincial Clinical Research Center for Neurological Diseases
After 6 weeks, the patients receiving tanezumab experienced a significant reduction in LBP compared to that of the other two groups
The peptide sequence, alanine-histidine-lysine bound to copper, was chosen because of how it interacts with growth factor receptors and anti-apoptotic pathways
Quality Indicators Legitimate peptide suppliers demonstrate commitment to quality through several verifiable practices
Because it does not suppress appetite, it can theoretically be combined with GLP-1 agonists to add a lipolytic component to the appetite suppression mechanism, though clinical data on this combination is lacking
